Immune Thrombocytopenia (ITP) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Summary
This reports provides a data-driven overview of the current and future competitive landscape in ITP therapeutics.
There will be more than 1.6 million diagnosed prevalent cases of ITP in 2023 across 16 pharmaceutical markets.
There are four leading marketed innovator drugs for the treatment of ITP, majority of marketed products are thrombopoietin receptor agonist.
R&D activity in ITP is significant, with nine products in Phase III development.
Novartis has sponsored the highest number of clinical trials (nine) in ITP over the past 10 years.
In deals involving ITP assets, licensing agreements are the most common type of deal globally.
New innovator drugs are expected to enter the ITP market only after the next two years.
Scope
GlobalData’s Immune Thrombocytopenia (ITP) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include -
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook